Comparison · NCT05039086-deaths
PDE5 Inhibitors vs Endothelin Receptor Antagonists: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PDE5 Inhibitors vs Endothelin Receptor Antagonists: deaths from any cause. Trial comparisons, record NCT05039086-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05039086-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.113 | 0.102 | 0.125 | wilson | |
| Risk in group 2 | 0.141 | 0.129 | 0.154 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0277 | -0.0449 | -0.0105 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.803 | 0.701 | 0.921 | log | |
| Odds ratio, group 1 over group 2 | 0.778 | 0.666 | 0.909 | log | |
| Number needed to treat, for one fewer death from any cause on PDE5 Inhibitors than on Endothelin Receptor Antagonists | 36.1 | 22.3 | 95 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PDE5 Inhibitors | Exposure group~PDE5 inhibitor: PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group. | 327 | 2,888 | EG000 |
| Group 2 | Endothelin Receptor Antagonists | Reference group~Endothelin Receptor Antagonists: Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group. | 407 | 2,888 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
- NCT number
- NCT05039086
- Phases
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- PDE5 inhibitor, Endothelin Receptor Antagonists
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2024-02-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05039086?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05039086-deaths